Boston Scientific Corporation (BSX) Shares Bought by Tavio Capital LLC

Tavio Capital LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 11.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,694,366 shares of the medical equipment provider’s stock after buying an additional 180,000 shares during the period. Boston Scientific Corporation makes up 20.1% of Tavio Capital LLC’s portfolio, making the stock its 2nd largest holding. Tavio Capital LLC owned 0.12% of Boston Scientific Corporation worth $49,425,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Acrospire Investment Management LLC grew its stake in Boston Scientific Corporation by 157.3% in the 2nd quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after buying an additional 3,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in Boston Scientific Corporation by 14.3% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after purchasing an additional 720 shares during the period. San Francisco Sentry Investment Group CA bought a new stake in Boston Scientific Corporation in the 2nd quarter valued at about $191,000. Peddock Capital Advisors LLC bought a new stake in Boston Scientific Corporation in the 2nd quarter valued at about $201,000. Finally, Ironwood Investment Counsel LLC bought a new stake in Boston Scientific Corporation in the 3rd quarter valued at about $204,000. Institutional investors and hedge funds own 90.47% of the company’s stock.

A number of research firms have issued reports on BSX. Royal Bank Of Canada reissued a “buy” rating and issued a $31.00 price objective on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. UBS AG reissued a “buy” rating and issued a $31.00 price objective (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. Zacks Investment Research raised shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 31st. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, August 9th. Finally, Cowen and Company reissued an “outperform” rating and issued a $31.00 price objective on shares of Boston Scientific Corporation in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Boston Scientific Corporation has a consensus rating of “Buy” and a consensus price target of $30.77.

COPYRIGHT VIOLATION NOTICE: This article was published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/02/boston-scientific-corporation-bsx-shares-bought-by-tavio-capital-llc.html.

In other Boston Scientific Corporation news, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $26.87, for a total transaction of $416,485.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Maulik Nanavaty sold 27,031 shares of Boston Scientific Corporation stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $27.08, for a total transaction of $731,999.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 498,864 shares of company stock valued at $14,299,469. 0.74% of the stock is currently owned by company insiders.

Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the business posted $0.27 earnings per share. Boston Scientific Corporation’s revenue for the quarter was up 5.6% on a year-over-year basis.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit